Bispecifics vs CAR T-Cell Therapy: Which Is Better in Relapsed/Refractory Multiple Myeloma?

Retrieved on: 2022-10-01 14:32:17

Tags for this article:

Click the tags to see associated articles and topics

Bispecifics vs CAR T-Cell Therapy: Which Is Better in Relapsed/Refractory Multiple Myeloma?. View article details on hiswai:

Excerpt

Bispecific antibodies are antibodies that have 2 binding sites; ... a proteasome inhibitor, and an anti-CD38 monoclonal antibody.6.

Article found on: www.targetedonc.com